Neurogranin Levels in Cerebrospinal Fluid – A New Addition to the Alzheimer Disease Diagnostic Toolbox

Recent biomarker studies suggest that the pathological changes of Alzheimer disease (AD) start with Aβ deposition as early as 20 to 30 years prior to symptom onset,1 a window of time that holds promise for therapeutic intervention to reverse or slow down the disease. Aβ deposition is believed to be followed by tangle pathology and neurodegeneration (as reflected by concentrations of tau protein in cerebrospinal fluid [CSF]) some 10 to 20 years later and closer to clinical disease onset, which resonates well with the Aβ cascade hypothesis in which Aβ is regarded as the trigger and potentially also the driver in the disease process.

Are you or someone you love diagnosed with Alzheimer’s? Help us in the fight for better treatments. Join one of our clinical research studies on Alzheimer’s today.




For those who are struggling with memory loss, a memory screen is a step in the right direction to keeping their minds healthy. Apply for a FREE memory screen today!